G2 Research Announces Availability Of Pharmacokinetic Modeling Data Sets

Oct. 23, 2008 - PRLog -- Lake Tahoe, CA-  G2 Research , a company focused on the marketing and use of data, models and tools to develop pharmacokinetic models, today announced the commercial availability of its high quality in vivo and in vitro assay data suitable for building PK models.

The ADME MODEL Data set is immediately available and contains assay data for nearly 600 compounds, including more than 9,500 individual data points.
•   Caco-2 at 2 pH values with A/B B/A data
•   Thermodynamic solubility at 5 pH values
•   Blood plasma partitioning
•   Protein binding (human and rat)
•   Intestinal segment permeability measured in rabbit and rat intestinal tissue A/B and B/A
•   Multiple concentration human hepatocyte assay data
•   CYP 2D6 and 3A4 inhibition

A related set of human in vivo data corresponding to the compounds used in the in vitro assays is also available.  These human data have been analyzed by a single set of algorithms to provide target in vivo profiles for the development of ADME models.

A comprehensive exclusive in vivo rat ADME data set not yet utilized in any commercial model is also available.

Based on original research conducted by NaviCyte, Inc. and acquired by Trega Biosciences in 1998 and subsequently by LION bioscience in 2001, the data sets consist of individual in vitro and in vivo assay data points of hundreds of hand selected pharmaceutical compounds.  These data sets were used in the development of the iDEA™ and PK Express™ pharmacokinetic simulation models which were marketed by these companies.

The compounds represented in the data sets were chosen to produce robust, diverse data pools of in vitro and human pharmacokinetic clinical data, consisting of both drug development successes and failures, to train ADME models.

“What makes the data sets unique” says Founder and President Dr. George Grass, “is that all the data has been obtained using rigorous Standard Operating Procedures, collected in one lab, often by a single technician and so is far more consistent than anything that has been previously in the public domain. In the past, customers of the models, which were developed from these data sets, were demanding access to the underlying data but could not obtain access. Many wanted to use the data in their own proprietary models. Now we are making the data commercially available for the first time”.

The data is provided in Oracle, Excel or flat text file format. Compound name, structure, assay data as well as complete assay protocols are provided.
In addition to the currently available datasets, G2 Research will make available many of the development tools and the models which were part of the iDEA™ and PK Express™ simulation products and will license technology covered under its patents.

For more information about the data sets or the assays protocols contact G2 Research at info@admemodel.com  and visit http://www.admedata.com


About G2 Research, Inc.
G2 Research Inc, founded in 2001, provides consulting services to pharmaceutical organizations, primarily in the area of drug delivery and predictive pharmacokinetics.  Since acquiring the assets of the iDEA™ and PK Express™ products from Lion bioscience, G2R is using these tools in its consulting business and making those assets available to the market. The initial offering is the high quality in-vitro and in-vivo ADME and pharmacology data sets specifically constructed for the purpose of building predictive models.  G2 licenses the data to pharmaceutical companies for internal research use under a variety of flexible commercial agreements.